Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Kenneth W. O’keefe bought 2,000 shares of the stock in a transaction on Monday, November 14th. The stock was purchased at an average price of $113.84 per share, with a total value of $227,680.00. Following the completion of the purchase, the director now owns 12,107 shares of the company’s stock, valued at $1,378,260.88. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 110.24 on Friday. Jazz Pharmaceuticals PLC has a 1-year low of $95.80 and a 1-year high of $160.00. The stock has a market cap of $6.60 billion, a PE ratio of 19.28 and a beta of 1.35. The stock’s 50 day moving average is $116.61 and its 200-day moving average is $134.45.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $2.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.61 by $0.04. Jazz Pharmaceuticals PLC had a net margin of 24.81% and a return on equity of 30.50%. The company earned $374 million during the quarter, compared to analyst estimates of $389.34 million. During the same quarter in the previous year, the company posted $2.52 EPS. The company’s quarterly revenue was up 9.8% on a year-over-year basis. On average, analysts predict that Jazz Pharmaceuticals PLC will post $9.97 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

JAZZ has been the subject of several recent analyst reports. BMO Capital Markets restated an “outperform” rating and issued a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Sunday, July 31st. Mizuho lowered their price objective on shares of Jazz Pharmaceuticals PLC from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, August 10th. Piper Jaffray Cos. lowered their price objective on shares of Jazz Pharmaceuticals PLC from $188.00 to $178.00 and set an “overweight” rating for the company in a research note on Wednesday, August 10th. Barclays PLC reiterated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, August 10th. Finally, Goldman Sachs Group Inc. reiterated a “buy” rating and set a $195.00 price objective (down from $196.00) on shares of Jazz Pharmaceuticals PLC in a research note on Thursday, August 11th. Four research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $178.25.

Several hedge funds and other institutional investors have recently modified their holdings of JAZZ. Price T Rowe Associates Inc. MD boosted its position in shares of Jazz Pharmaceuticals PLC by 3.0% in the third quarter. Price T Rowe Associates Inc. MD now owns 108,230 shares of the specialty pharmaceutical company’s stock valued at $13,148,000 after buying an additional 3,130 shares during the last quarter. Pioneer Investment Management Inc. boosted its position in shares of Jazz Pharmaceuticals PLC by 36.4% in the third quarter. Pioneer Investment Management Inc. now owns 643,783 shares of the specialty pharmaceutical company’s stock valued at $78,207,000 after buying an additional 171,694 shares during the last quarter. Xact Kapitalforvaltning AB acquired a new stake in shares of Jazz Pharmaceuticals PLC during the third quarter worth $1,574,000. Highbridge Capital Management LLC acquired a new stake in shares of Jazz Pharmaceuticals PLC during the third quarter worth $329,000. Finally, Gotham Asset Management LLC boosted its stake in shares of Jazz Pharmaceuticals PLC by 45.4% in the third quarter. Gotham Asset Management LLC now owns 153,251 shares of the specialty pharmaceutical company’s stock worth $18,617,000 after buying an additional 47,847 shares in the last quarter. Institutional investors and hedge funds own 87.60% of the company’s stock.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.